Abstract: The present invention is related to the use of the GHRP-6 and one structural analogue as molecular adjuvants for vaccines. Among other applications, these vaccines may be employed for preventing diseases caused by infectious agents, like viruses, bacteria and ectoparasites, that affect mammals, birds and aquatic organisms. The GHRP-6 and its analogue A233 are effectives as adjuvants when they are combine with a given antigen, since they enhance the specific immune response against it.
Type:
Grant
Filed:
October 30, 2017
Date of Patent:
November 23, 2021
Assignee:
CENTRO DE INGENIERIA GENÉTICA BIOTECNOLOGIA
Inventors:
Rebeca Martínez Rodríguez, Liz Hernandez Perez, Lázaro Gil González, Yamila Carpio González, Mario Pablo Estrada García
Abstract: The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.
Type:
Application
Filed:
March 21, 2012
Publication date:
April 24, 2014
Applicant:
CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIA
Inventors:
María del Carmen Abrahantes Pérez, Glay Chinea Santiago, Eduardo Martínez Díaz, Hilda Elisa Garay Perez, Osvaldo Reyes Acosta, Ernesto Lopez Mola, Cruz Matilde Lopez Abad, Sonia Gonzalez Blanco
Abstract: The present invention relates to the use of a peptide of P0 ribosomal protein in the manufacture of a vaccine composition to control of ectoparasite infestations and therefore the transmission of their associated pathogens. This peptide is located between 267 and 301 amino acids of the P0 protein, and can be obtained by recombinant means or by chemical synthesis. This peptide can be fused to a carrier protein or peptide, or an immuno-carrier and be included in an oily formulation. The formulations comprising the peptide vaccine confer protection against ticks and ectoparasites known as “sea lice” without generating autoimmunity in the host organism. Among these ticks may be mentioned species as Rhipicephalus microplus, Rhipicephalus sanguineus and Ixodes scapularis, and between sea lice are those of the Caligus and Lepeophtheirus genera.
Type:
Application
Filed:
September 26, 2011
Publication date:
October 17, 2013
Applicant:
CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIA
Inventors:
Alina Rodriguez Mallon, Erlinda Fernández Díaz, Mario Pablo Estrada Garcia, Yamila Carpio González